From: Proceedings of the 28th European Paediatric Rheumatology Congress (PReS 2022)
Variables | All patients (n=203) | Cluster 1 (n=94) | Cluster 2 (n=109) | P value |
---|---|---|---|---|
Number of the patients | 203 (100.0) | 94 (46.3) | 109 (53.7) | - |
Sex/Female | 133 (65.5) | 68 (72.3) | 65 (59.6) | 0.058 |
Age at disease diagnosis, years | 7 (1-16) | 7 (1-16) | 7 (1.5-15) | 0.353 |
ESR at diagnosis, mm/h | 17 (1-100) | 23.5 (2-100) | 10 (1-97) | 0.002 |
CRP at diagnosis, mg/L | 3.7 (0.03-233) | 6.8 (0.04-125) | 3.3 (0.03-233) | 0.022 |
The number of affected joints | 2 (1-26) | 5 (1-26) | 2 (1-6) | <0.001 |
Affected joints | ||||
 Hip | 24 (11.8) | 14 (14.9) | 10 (9.2) | 0.208 |
 Knee | 168 (82.8) | 59 (62.8) | 109 (100.0) | <0.001 |
 Ankle | 70 (34.5) | 49 (52.1) | 21 (19.3) | <0.001 |
 Shoulder | 6 (3.0) | 6 (6.4) | 0 (0.0) | 0.009* |
 Elbow | 33 (16.3) | 33 (35.1) | 0 (0.0) | <0.001 |
 Wrist | 47 (23.2) | 47 (50.0) | 0 (0.0) | <0.001 |
 Small joints | 52 (25.6) | 52 (55.3) | 0 (0.0) | <0.001 |
 Cervical vertebrae | 3 (1.5) | 3 (3.2) | 0 (0.0) | 0.098* |
 TMJ | 5 (2.5) | 5 (5.3) | 0 (0.0) | 0.020 |
Treatments | ||||
 İAE | 106 (52.2) | 34 (36.2) | 72 (66.1) | <0.001 |
 Steroids | 98 (48.3) | 57 (60.6) | 41 (37.6) | 0.001 |
 DMARD | 188 (92.6) | 92 (97.9) | 96 (88.1) | 0.008 |
 Biologics | 88 (43.3) | 58 (61.7) | 30 (27.5) | <0.001 |
 Remission at 12 months | 100 (49.3) | 36 (38.5) | 64 (58.7) | 0.004 |
 Relapse of arthritis | 124 (61.1) | 62 (66.0) | 62 (56.9) | 0.186 |
 Remission at last visit | 154 (75.9) | 63 (67.0) | 91 (83.5) | 0.006 |